CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs
This article was originally published in The Pink Sheet Daily
Executive Summary
In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.
You may also be interested in...
Outgoing PhRMA Exec: Industry Needs To Better Tell Its Innovation Story
The brand drug industry’s success in tackling COVID-19 followed by swift political loss with the Inflation Reduction Act is in part due to the public’s continued knowledge gaps about the medical innovation ecosystem, outgoing PhRMA VP Jenny Bryant tells Pink Sheet in an interview.
Reimbursement Briefs: Medicaid Savings, Kcentra Payment, Formulary Discrimination Concerns
Cost reductions in Medicaid associated with increased drug use; Medicare add-on payments for Kcentra extended; patient groups seek formulary non-discrimination provisions in HHS rule.
The Sovaldi Anniversary? Burgess Wants Part D Milestone To Change How Gov’t Values Rx Spending
Congressional budget projections should use longer time horizons, Vice-Chair of House Energy and Commerce Health Subcommittee argues; meanwhile former FDA Commissioner suggests costly drugs could be paid for on a mortgage model.